Emory University is hopeful that a new study will lead to a breakthrough in childhood cancer treatment. The university says new research from a partnership with Australia's QIMR Berghofer Medical Research Institute shows a potential new targeted treatment for brain cancer in children.
In a recent paper published in the journal Nature Communications, the researchers say the novel drug CT-179 was shown to be effective in killing tumor cells in preclinical models using mice.
The drug specifically targeted tumor cells that are resistant to standard treatments, which could lead to more effective and less toxic treatments.
The researchers say the drug could possibly apply to other brain cancers as well.
Timothy Gershon, MD, PhD was one of the study's lead researchers. He is an Emory University Professor and also a pediatric neurologist at Children’s Healthcare of Atlanta and director of the Children’s Center for Neurosciences Research.
Children's Center for Neurosciences Research (CCNR)
With administration once a day, Alyftrek offers an additional treatment option for patients with cystic fibrosis and provides a simpler dosing regimen for people with cystic fibrosis, as compared to twice daily for other modulators.
Center for Cystic Fibrosis and Airways Disease Research (CF-AIR)
The annual award is given to care centers that have gone above and beyond to collaborate with their local CF Foundation chapter
Center for Cystic Fibrosis and Airways Disease Research (CF-AIR)
Results may help increase access to the new therapy for teens and young adults
Aflac Cancer and Blood Disorders Center (Aflac)
We are excited to announce our 2024 pilot grant awardees!
As announced in January, Lucky Jain, MD, MBA will be retiring from his role as chair of the Department of Pediatrics at the end of the year. Lucky leaves a lasting impact on Emory and the pediatric community, and I am immensely grateful for his vision and leadership.
Awardees for the eighth cycle of theWarshaw Fellow Research Awards and Buchter Resident Research Awards have been announced.
Emory University and Children’s Healthcare of Atlanta were one of 10 sites to take part in the first stage of a clinical trial of the recently FDA-approved use of Omalizumab to reduce allergic reactions to multiple food allergies.
